$171 Million is the total value of Knoll Capital Management, LLC's 33 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BHVN | Biohaven Pharmactl Hldg Co L | $136,181,000 | +3.6% | 900,844 | 0.0% | 79.57% | +6.1% | |
| ENTX | Entera Bio Ltd | $2,584,000 | -21.8% | 2,484,275 | 0.0% | 1.51% | -19.9% | |
| Anavex Life Sciences Corp | $2,175,000 | +3.1% | 210,789 | 0.0% | 1.27% | +5.6% | ||
| ORGS | Orgenesis, Inc. | $1,869,000 | -41.3% | 1,316,364 | 0.0% | 1.09% | -39.9% | |
| CVS | CVS Health Corp | $1,384,000 | +3.0% | 14,500 | 0.0% | 0.81% | +5.5% | |
| BAH | Booz Allen Hamilton HLDG CORcl a | $1,200,000 | +2.1% | 13,000 | 0.0% | 0.70% | +4.5% | |
| TMO | Thermo Fischer Scientific Inc | $1,066,000 | -6.6% | 2,100 | 0.0% | 0.62% | -4.3% | |
| APLT | Applied Therapeutics Inc | $1,006,000 | -1.9% | 1,082,123 | 0.0% | 0.59% | +0.3% | |
| MO | Altria Group Inc | $917,000 | -3.3% | 22,700 | 0.0% | 0.54% | -0.9% | |
| V | Visa | $862,000 | -9.7% | 4,850 | 0.0% | 0.50% | -7.5% | |
| CRBP | Corbus Pharmaceuticals HLDGS | $833,000 | -34.6% | 5,045,870 | 0.0% | 0.49% | -33.0% | |
| GLW | Corning Inc | $773,000 | -7.8% | 26,600 | 0.0% | 0.45% | -5.4% | |
| AEM | AGNICO EAGLE MINES LTD | $650,000 | -7.7% | 15,393 | 0.0% | 0.38% | -5.5% | |
| FNV | FRANCO NEV CORP | $585,000 | -9.3% | 4,900 | 0.0% | 0.34% | -7.1% | |
| MMX | MAVERIX METALS INC | $553,000 | -23.0% | 165,000 | 0.0% | 0.32% | -21.2% | |
| SILV | SILVERCREST METALS INC | $553,000 | -35.8% | 100,000 | 0.0% | 0.32% | -34.2% | |
| WPM | Wheaton Precious metals | $534,000 | -10.1% | 16,500 | 0.0% | 0.31% | -8.0% | |
| OR | OSISKO GOLD ROYALTIES LTD | $529,000 | -21.7% | 235,000 | 0.0% | 0.31% | -19.9% | |
| PAAS | PAN AMERN SILVER CORP | $468,000 | -44.9% | 29,500 | 0.0% | 0.27% | -43.7% | |
| EQX | EQUINOX GOLD CORP | $361,000 | -62.8% | 99,000 | 0.0% | 0.21% | -61.9% | |
| MRTX | Mirati Therapeutics, Inc | $349,000 | +3.9% | 5,000 | 0.0% | 0.20% | +6.2% | |
| BTAI | Bioxcel Therapeutics Inc | $236,000 | +156.5% | 20,000 | 0.0% | 0.14% | +160.4% | |
| Context Therapeutics Ins | $155,000 | -47.6% | 139,520 | 0.0% | 0.09% | -46.2% | ||
| ANVS | Annovis Bio Inc | $147,000 | -8.7% | 14,210 | 0.0% | 0.09% | -6.5% | |
| ORMP | Oramed Pharmaceuticals Inc | $130,000 | +41.3% | 20,000 | 0.0% | 0.08% | +43.4% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Aldeyra Therapeutics Inc | 35 | Q3 2023 | 31.6% |
| Corbus Pharmaceuticals HLDGS | 30 | Q3 2022 | 46.5% |
| Abeona Therapeutics Inc | 30 | Q3 2022 | 34.8% |
| Biohaven Pharmactl Hldg Co L | 26 | Q3 2023 | 79.6% |
| Entera Bio Ltd | 22 | Q3 2023 | 7.8% |
| Ampio Pharmaceuticals Inc. | 21 | Q2 2018 | 11.0% |
| Soligenix Inc. | 20 | Q3 2022 | 1.7% |
| Eiger Biopharmaceuticals Inc | 19 | Q3 2022 | 5.8% |
| Applied Therapeutics Inc | 18 | Q3 2023 | 19.7% |
| Alcobra Ltd | 18 | Q3 2017 | 6.5% |
View Knoll Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| HOOKIPA Pharma Inc. | June 20, 2023 | 5,517,385 | 6.8% |
| Applied Therapeutics Inc. | January 23, 2023 | 3,450,000 | 7.2% |
| Orgenesis Inc. | August 14, 2020 | 1,316,364 | 5.9% |
| Corbus Pharmaceuticals Holdings, Inc. | February 14, 2020 | 5,045,870 | 7.1% |
| ABEONA THERAPEUTICS INC. | February 14, 2018 | 2,359,767 | 5.0% |
| SOLIGENIX, INC. | November 13, 2017 | 870,000 | 9.9% |
| ABEONA THERAPEUTICS INC. | February 14, 2017 | 2,359,767 | 5.9% |
| ALCOBRA LTD. | February 14, 2017 | 1,205,498 | 4.4% |
| Ampio Pharmaceuticals, Inc. | February 14, 2017 | 2,738,322 | 4.8% |
| RITTER PHARMACEUTICALS INC | February 14, 2017 | 952,434 | 8.2% |
View Knoll Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-01-16 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-04 |
| 13F-HR | 2023-08-15 |
| SC 13G | 2023-06-20 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-01-23 |
| 13F-HR | 2022-11-14 |
View Knoll Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.